Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 4,938 Shares of Stock

Posted by Stanley Muller on Sep 17th, 2026

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) Director Melissa Epperly sold 4,938 shares of the firm’s stock in a transaction on Tuesday, September 15th. The shares were sold at an average price of $39.74, for a total transaction of $196,236.12. Following the transaction, the director owned 9,900 shares in the company, valued at $393,426. This represents a 33.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Roivant Sciences Price Performance

NASDAQ:ROIV traded up $0.41 during trading hours on Thursday, reaching $39.98. The company’s stock had a trading volume of 7,603,971 shares, compared to its average volume of 6,302,233. The company has a market cap of $28.88 billion, a price-to-earnings ratio of -75.43 and a beta of 1.12. Roivant Sciences Ltd. has a one year low of $14.50 and a one year high of $42.50. The business’s 50-day moving average is $36.04 and its 200-day moving average is $31.89.

Roivant Sciences (NASDAQ:ROIV – Get Free Report) last posted its earnings results on Friday, August 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%.The company had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. On average, sell-side analysts predict that Roivant Sciences Ltd. will post -2 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ROIV. UBS Group set a $55.00 price objective on shares of Roivant Sciences in a research note on Wednesday, September 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a report on Tuesday, August 25th. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a research report on Thursday, May 21st. HC Wainwright upped their price target on shares of Roivant Sciences from $41.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, September 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Roivant Sciences in a research report on Wednesday, August 19th. One investment analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $41.42.

Check Out Our Latest Analysis on Roivant Sciences

Hedge Funds Weigh In On Roivant Sciences

Several large investors have recently bought and sold shares of ROIV. Goldman Sachs Group Inc. grew its position in Roivant Sciences by 365.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 10,982,633 shares of the company’s stock worth $238,323,000 after purchasing an additional 8,621,567 shares during the last quarter. Norges Bank acquired a new position in Roivant Sciences in the 4th quarter valued at approximately $112,750,000. Jefferies Financial Group Inc. bought a new stake in shares of Roivant Sciences in the 4th quarter worth approximately $76,272,000. Baker BROS. Advisors LP grew its holdings in shares of Roivant Sciences by 47.4% during the 4th quarter. Baker BROS. Advisors LP now owns 5,555,017 shares of the company’s stock worth $120,544,000 after purchasing an additional 1,787,244 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Roivant Sciences by 179.0% during the 2nd quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company’s stock worth $95,124,000 after purchasing an additional 1,724,588 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences Ltd. is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with significant unmet medical needs. The company concentrates on areas including immunology, dermatology, oncology and other specialty conditions, using a combination of internally developed programs, external licensing and strategic acquisitions.

Roivant organizes many of its drug-development activities through subsidiary companies known as “Vants.” These businesses are designed to advance individual therapeutic programs or groups of related assets, while Roivant provides operational, scientific and strategic support.